|
|
News Breaks | | | | November 12, 2012 | | 18:05 EDT |  | MNOV | MedicNova announces publication of positive phase 2 clinical results
MediciNova announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication reports on two Phase 2a clinical trials conducted by MediciNova, MN-221-CL-004 and MN-221-CL-005, which assessed the safety, tolerability, and FEV1 improvements in mild-moderate and moderate-to-severe asthmatics, respectively. MN-221 is designed to treat acute exacerbations via intravenous infusion, bypassing constricted airways to deliver the drug directly to the lungs. Preclinical studies showed MN-221 to have a high affinity for the beta(2)-adrenergic receptor, found primarily in the lungs, and a much lower affinity for the beta(1)-adrenergic receptor found primarily in cardiac tissue. These studies showed no worrisome increase in heart rate when MN-221 was administered. | |
|
News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks. |
|
|
| May 9, 2013 | | 10:01 EDT |  | MNOV | MedicNova falls 21.6%
MedicNova is down 21.6%, or $1.00, to $3.63 | | | May 8, 2013 | | 17:33 EDT |  | MNOV | MedicNova reports Q1 EPS (14c), one estimate (13c)
| |
|
|
|
|
|
|
